FIELD: medicine; immunology; oncology.
SUBSTANCE: invention can be used to predict disease progression over the next three months in cancer patients with solid tumours. The following clinical and immunological parameters of the patient are determined: gender, age of the patient, oncological diagnosis, stage of the disease, prognostic group of the disease, duration of treatment, duration of the disease, type of treatment at the current stage and type of previous treatment, content of T- and B-lymphocytes, natural killer cells, cytotoxic lymphocytes, T-helper cells, and the value of the immunoregulatory index. The obtained information is transferred to the algorithm for constructing an ensemble of decision trees. During the operation of the ensemble of decision trees, the result of an integral assessment of the probability of process progression is obtained. If the probability is greater than or equal to 0.3812, a high probability of disease progression over the next three months is predicted.
EFFECT: method provides an objective assessment of the criteria for stopping, resuming and changing therapy for cancer patients with solid tumours based on the analysis of clinical and immunological factors using a predictive algorithm for constructing an ensemble of decision trees based on gradient boosting.
1 cl, 3 dwg, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PREDICTING OUTCOME OF ADVANCED CUTANEOUS MELANOMA DURING THERAPY WITH CHECKPOINT INHIBITORS | 2023 |
|
RU2810433C1 |
METHOD FOR DETERMINING THE DEGREE OF AGGRESSIVENESS OF THE COURSE OF SKIN MELANOMA | 2021 |
|
RU2754100C1 |
METHOD FOR PREDICTING CLINICAL COURSE OF HIGHLY DIFFERENTIATED NEUROENDOCRINE PANCREATIC TUMORS | 2020 |
|
RU2747679C1 |
METHOD FOR PREDICTION OF RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-EGFR THERAPY | 2024 |
|
RU2820402C1 |
METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
METHOD FOR ASSESSING RISK OF PROGRESSION OF METASTATIC COLORECTAL CANCER AFTER ANTI-VEGF THERAPY | 2024 |
|
RU2823505C1 |
PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
BRAF KINASE INHIBITOR N-(3-(5-(4-CHLOROPHENYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-CARBONIL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULFONAMIDE | 2018 |
|
RU2687107C1 |
N-(3-(5-(4-CHLOROPHENYL)-1N-PYRAZOLO[3,4-B]PYRIDINE-3-CARBONYL)-2,4-DIFLUOROPHENYL)PROPANE-1-SULPHONAMIDE CRYSTALLINE FORM, ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION AND MEDICINE | 2018 |
|
RU2678455C1 |
METHOD FOR PREDICTING THE COURSE OF LOW-DIFFERENTIATED GLIAL TUMORS BASED ON A CYTOKINE MICROENVIRONMENT | 2020 |
|
RU2741690C1 |
Authors
Dates
2024-03-05—Published
2022-03-29—Filed